Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 154
Immunization Safety Review: Vaccines and Autism REFERENCES AAP (American Academy of Pediatrics) and USPHS (U.S. Public Health Service). 1999. Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (PHS). Pediatrics 104(3 Pt 1):568-9. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23(2):185-8. APA (American Psychiatric Association). 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA. APA. 2000. Diagnostic and Statistical Manual of Mental Disorders; Text Revision. 4th ed. Washington, DC: APA. Aposhian HV. 2004. Presentation to the Immunization Safety Review Committee. A Toxicologist’s View of Thimerosal and Autism. Washington, DC. Araghi-Niknam M, Fatemi SH. 2003. Levels of Bcl-2 and P53 are altered in superior frontal and cerebellar cortices of autistic subjects. Cell Mol Neurobiol 23(6):945-52. Arvai JL. 2003. Using risk communication to disclose the outcome of a participatory decisionmaking process: effects on the perceived acceptability of risk-policy decisions. Risk Anal 23(2):281-9. Atkinson WL, Orenstein WA, Krugman S. 1992. The resurgence of measles in the United States, 1989-1990. Annu Rev Med 43(6):451-63. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. 1995. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25(1):63-77. Ball LK, Ball R, Pratt RD. 2001. An assessment of thimerosal use in childhood vaccines. Pediatrics. 107(5):1147-54. Baskin D. 2004. Presentation to the Immunization Safety Review Committee. Washington, DC. Baskin DS, Ngo H, Didenko VV. 2003. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci 74(2):361-8. Bauman M, Kemper T. 1997. Neuroanatomic observations of the brain in autism. Bauman M, Kemper T, eds. The Neurobiology of Autism. Baltimore: Johns Hopkins University Press. Pp. 119-45. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. 2001. Autism: a novel form of mercury poisoning . Med Hypotheses 56(4):462-71. Bertrand J, Mars A, Boyle C, Bove F, Yeargin-Allsopp M, Decoufle P. 2001. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 108(5):1155-61. Black C, Kaye JA, Jick H. 2002. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. British Med J 325(7361):419-21. Blaxill M. 2001. Presentation to Immunization Safety Review Committee. Rising Incidence of Autism: Association with Thimerosal. Washington, DC. Bloch AB, Orenstein WA, Stetler HC, Wassilak SG, Amler RW, Bart KJ, Kirby CD, Hinman AR. 1985. Health impact of measles vaccination in the United States. Pediatrics 76(4):524-32. Bradstreet J. 2004. Presentation to the Immunization Safety Review Committee. Biological Evidence of Significant Vaccine Related Side-effects Resulting in Neurodevelopmental Disorders. Washington, DC. Bradstreet J, Geier D, Kartzinel J, Adams J, Geier M. 2003. A case-control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg 8(3):76-9. Bristol MM, Cohen DJ, Costello EJ, Denckla M, Eckberg TJ, Kallen R, Kraemer HC, Lord C, Maurer R, McIlvane WJ, Minshew N, Sigman M, Spence MA. 1996. State of the science in autism: report to the National Institutes Health. J Autism Dev Disord 26(2):121-54.
OCR for page 155
Immunization Safety Review: Vaccines and Autism Burd L, Fisher W, Kerbeshian J. 1987. A prevalence study of pervasive developmental disorders in North Dakota. J Am Acad Child Adolesc Psychiatry 26(5):700-3. California Department of Developmental Services. 2003. Autistic Spectrum Disorders. Changes in the California Caseload. An Update: 1999 Through 2002. Sacramento, CA: California Health and Human Services Agency. California Health and Human Services Agency, Department of Developmental Services. 1999. Changes in the Population of Persons with Autism and Pervasive Developmental Disorders in California’s Developmental Services System: 1987 Through 1998. Carbone KM, Rubin SA, Pletnikov M. 2002. Borna disease virus (BDV)-induced model of autism: application to vaccine safety test design. Mol Psychiatry 7 (Suppl 2):S36-7. Casanova MF, Buxhoeveden DP, Switala AE, Roy E. 2002. Neuronal density and architecture (Gray Level Index) in the brains of autistic patients. J Child Neurol 17(7):515-21. CDC (Centers for Disease Control and Prevention). 1991. Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP). Morb Mortal Wkly Rep. 40(RR-13):1-19 . CDC. 1997. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC. Morb Mortal Wkly Rep 46(RR–11):1-20. CDC. 1998. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 47(RR–8):1-57. CDC. 1999a. Autism spectrum disorders among children. [Online] Available: http://www.cdc.gov/ncbddd/fact/tasdfs.htm [accessed 2001]. CDC. 1999b. Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. Morb Mortal Wkly Rep 48(26):563-5. CDC. 2000. Measles—United States, 1999. Morb Mortal Wkly Rep 49(25):557-60. CDC. 2002. Estimated vaccination coverage with individual vaccines by 3 months of age by state and immunization action plan area- US, National Immunization Survey Q1/2001-Q4/2001. Available [online]: http://www.cdc.gov/nip/coverage/NIS/01/TAB4-3months_iap.htm [accessed December, 2002]. CDC. 2003a. ACIP expands recommendation for vaccinating children in the 2004-05 flu season. [Online] Available at: www.cdc.gov/flu/professionals/acip/acipchild0405.htm. CDC. 2003b. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 52(RR-8):1-35. CDC. 2004. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 53:1-40. Chen RT. 1994. Special methodological issues in pharmacoepidemiology studies of vaccine safety. Strom BL, ed. Pharmacoepidemiology. 2nd ed. New York: Wiley. Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. 1999. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 14(6):388-94. Connolly AM, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. 1999. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 134(5):607-13. Cook EH Jr, Perry BD, Dawson G, Wainwright MS, Leventhal BL. 1993. Receptor inhibition by immunoglobulins: specific inhibition by autistic children, their relatives, and control subjects. J Autism Dev Disord 23(1):67-78. Courchesne E, Carper R, Akshoomoff N. 2003. Evidence of brain overgrowth in the first year of life in autism. JAMA 290(3):337-44. Croen LA, Grether JK, Hoogstrate J, Selvin S. 2002. The changing prevalence of autism in California. J Autism Dev Disord 32(3):207-15.
OCR for page 156
Immunization Safety Review: Vaccines and Autism Croonenberghs J, Wauters A, Devreese K, Verkerk R, Scharpe S, Bosmans E, Egyed B, Deboutte D, Maes M. 2002. Increased serum albumin, gamma globulin, immunoglobulin IgG, and IgG2 and IgG4 in autism. Psychol Med 32(8):1457-63. Dales L, Hammer SJ, Smith N. 2001. Time trends in autism and in MMR immunization coverage in California. JAMA 285(9):1183-5. Daniels WW, Warren RP, Odell JD, Maciulis A, Burger RA, Warren WL, Torres AR. 1995. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 32(3):120-3. Davidovitch M, Glick L, Holtzman G, Tirosh E, Safir MP. 2000. Developmental regression in autism: maternal perception. J Autism Dev Disord 30(2):113-9. Davis R. 2004. Presentation to the Immunization Safety Review. Review of ‘Safety of Thimerosal-Containing Vaccines: a Two Phased Study of Computerized Health Maintenance Organization Databases.’ Washington, DC. DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. 1999. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 29(2):157-60. DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C. 2004. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan Atlanta. Pediatrics 113(2):259-66. DeWilde S, Carey IM, Richards N, Hilton SR, Cook DG. 2001. Do children who become autistic consult more often after MMR vaccination? British J Gen Pract. 51(464):226-7. Dickersin K, Braun L, Mead M, Millikan R, Wu AM, Pietenpol J, Troyan S, Anderson B, Visco F. 2001. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Health Expect 4(4):213-20. Evans H. 1998. Mercury. Environmental and Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven. Evers M, Cunningham-Rundles C, Hollander E. 2002. Heat shock protein 90 antibodies in autism. Mol Psychiatry 7(Suppl 2):S26-8. Farrington CP, Miller E, Taylor B. 2001. MMR and autism: further evidence against a causal association. Vaccine 19(27):3632-5. Fatemi SH, Halt AR, Stary JM, Realmuto GM, Jalali-Mousavi M. 2001. Reduction in anti-apoptotic protein Bcl-2 in autistic cerebellum. Neuroreport 12(5):929-33. FDA (Food and Drug Administration). 2001. Thimerosal content in some currently manufactured U.S. licensed vaccines (table). Accessed July, 2001. Web Page. Available at: http://www.fda.gov/cber/vaccine/thimcnt.htm. FDA. 2004a. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 31, 2004.) FDA. 2004b. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 2, 2004.) FDA. 2004c. VAERS reports of autism. (Email communication from Jane Woo, Food and Drug Administration, March 8, 2004.) FDA. 2004d. Table 1: Technical Review. (E-mail communication from William Egan, Food and Drug Administration, May 11, 2004.) FDA. 2004e. Thimerosal content in vaccines. (Email communication from Karen Midthun, Food and Drug Administration, May 7, 2004.) Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR. 1999. The screening and diagnosis of autistic spectrum disorders. J Autism Dev Disord 29(6):439-84. Fiumara A, Sciotto A, Barone R, D’Asero G, Munda S, Parano E, Pavone L. 1999. Peripheral lymphocyte subsets and other immune aspects in Rett syndrome. Pediatr Neurol 21(3):619-21.
OCR for page 157
Immunization Safety Review: Vaccines and Autism Folstein S, Rutter M. 1977. Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 18(4):297-321. Fombonne E. 1999. The epidemiology of autism: a review. Psychol Med 29(4):769-86. Fombonne E. 2001a. Is there an epidemic of autism? Pediatrics 411-13. Fombonne E. 2001b. Presentation to Immunization Safety Review Committee. Epidemiological Slide Set. Washington, DC. Fombonne E. 2001c. Presentation to Immunization Safety Review Committee. New Studies. Washington, DC. Fombonne E. 2002. Epidemiological trends in rates of autism. Mol Psychiatry 7 (Suppl 2):S4-6. Fombonne E. 2003. The prevalence of autism. JAMA 289(1):87-9. Fombonne E, Chakrabarti S. 2001. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 108(4):E58. Geier DA, Geier MR. 2003a. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 6(2):97-102. Geier M, Geier D. 2003b. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 228(6):660-4. Geier M, Geier D. 2003c. Pediatric MMR vaccination safety. Int Pediatrics 18(2):203-8. Geier MR, Geier DA. 2003d. Thimerosal in childhood vaccines, neurodevelopmental disorders, and heart disease in the United States. J Amer Phys Sur 8(1):6-11. Geier DA, Geier MR. 2004a. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit 10(3):PI33-9. Geier D, Geier M. 2004b. Presentation to the Immunization Safety Review Committee. From Epidemiology, Clinical Medicine, Molecular Biology, and Atoms, to Politics: A Review of the Relationship between Thimerosal and Autism. Washington, DC. Geier D, Geier M. 2004c. Submission to the Immunization Safety Review Committee. From Epidemiology, Clinical Medicine, Molecular Biology, and Atoms, to Politics: A Review of the Relationship Between Thimerosal and Autism. General Biologics Product Standards. 2000. Constituent materials. 21 CFR. 610.15. Gillberg C, Heijbel H. 1998. MMR and autism. Autism 2:423-4. Gillberg C, Wing L. 1999. Autism: not an extremely rare disorder. Acta Psychiatr Scand 99(6):399-406. Gillberg C, Steffenburg S, Schaumann H. 1991. Is autism more common now than ten years ago? British J Psychiatry 158:403-9. Greenberg M, Pellitteri O, Barton J. 1957. Frequency of defects in infants whose mothers had rubella during pregnancy. J Am Med Assoc 165(6):675-8. Gupta S, Aggarwal S, Heads C. 1996. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 26(4):439-52. Gupta S, Aggarwal S, Rashanravan B, Lee T. 1998. Th1- and Th2-like cytokines in CD4+ and CD8+ T cells in autism. J Neuroimmunol 85(1):106-9. Gurney JG, Fritz MS, Ness KK, Sievers P, Newschaffer CJ, Shapiro EG. 2003. Analysis of prevalence trends of autism spectrum disorder in Minnesota. Arch Pediatr Adolesc Med 157(7):622-7. Halsey NA, Goldman L. 2001. Balancing risks and benefits: primum non nocere is too simplistic. Pediatrics 108(2):466-7. Hill AB. 1965. The environment and disease: association or causation? Proc R Soc Med. 58:295-300. Hinestrosa C. 2001. What is Project Lead? (Slide Presentation- Hard Copy). Holmes AS, Blaxill MF, Haley BE. 2003. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol 22:277-85. Hornig M. 2004. Presentation to the Immunization Safety Review Committee. Etiologic Factors and Pathogenesis of Autism: Evidence from Clinical Studies and Animal Models. Washington, DC.
OCR for page 158
Immunization Safety Review: Vaccines and Autism Hornig M, Weissenbock H, Horscroft N, Lipkin WI. 1999. An infection-based model of neurodevelopmental damage. Proc Natl Acad Sci USA 96(21):12102-7. Hoshino Y, Kaneko M, Yashima Y, Kumashiro H, Volkmar FR, Cohen DJ. 1987. Clinical features of autistic children with setback course in their infancy. Jpn J Psychiatry Neurol 41(2):237-45. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. 2003. Association between thimerosal-containing vaccine and autism. JAMA 290(13):1763-6. Ingram JL, Stodgell CJ, Hyman SL, Figlewicz DA, Weitkamp LR, Rodier PM. 2000. Discovery of allelic variants of HOXA1 and HOXB1: genetic susceptibility to autism spectrum disorders [In Process Citation]. Teratology 62(6):393-405. IOM (Institute of Medicine). 1991. Adverse Events Following Pertussis and Rubella Vaccines. Washington, DC: National Academy Press. IOM. 1994a. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press. IOM. 1994b. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, DC: National Academy Press. IOM. 2001a. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism. Washington, DC: National Academy Press. IOM. 2001b. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders. Washington, DC: National Academy Press IOM. 2002a. Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders. Washington, DC: National Academy Press. IOM. 2002b. Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Washington, DC: National Academy Press. IOM. 2002c. Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer. Washington, DC: National Academies Press. IOM. 2003. Immunization Safety Review: Sudden Unexpected Death in Infancy. Washington, DC: National Academies Press. IOM. 2004. Immunization Safety Review: Influenza Vaccines and Neurological Complications. Washington, DC: National Academies Press. James J. 2004. Impaired transsulfuration and oxidative stress in autistic children: Improvement with targeted nutritional intervention. Submitted to the Immunization Safety Review Committee by Bradstreet J. Jyonouchi H, Sun S, Le H. 2001. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 120(1-2):170-9. Kaye JA, del Mar Melero-Montes M, Jick H. 2001. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. British Med J. 322(7284):460-3. Kielinen M, Rantala H, Timonen E, Linna SL, Moilanen I. 2004. Associated medical disorders and disabilities in children with autistic disorder: a population-based study. Autism 8(1):49-60. Kleinbaum DG, Kupper LL, Morgenstern H. 1982. Epidemiologic Research: Principles and Quantitative Methods. Belmont, CA: Lifetime Learning Publications, Wadsworth, Inc. Korvatska E, Van de Water J, Anders TF, Gershwin ME. 2002. Genetic and immunologic considerations in autism. Neurobiol Dis 9(2):107-25. Krause I, He XS, Gershwin ME, Shoenfeld Y. 2002. Brief report: immune factors in autism: a critical review. J Autism Dev Disord 32 (4):337-45. Kurita H. 1985. Infantile autism with speech loss before the age of thirty months. J Am Acad Child Psychiatry 24(2):191-6. Last JM, Abramson JH, Friedman GD, Porta M, Spasoff RA, Thuriaux M. 1995. A Dictionary of Epidemiology. 3rd ed. New York: Oxford University Press.
OCR for page 159
Immunization Safety Review: Vaccines and Autism Lord C. 1995. Follow-up of two-year-olds referred for possible autism. J Child Psychol Psychiatry 36(8):1365-82. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M. 2002. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 347(19):1477-82. Madsen KM, Lauritsen MB, Pedersen CB, Thorsen P, Plesner AM, Andersen PH, Mortensen PB. 2003. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 112(3 Pt 1):604-6. Maestro S, Muratori F, Cavallaro MC, Pei F, Stern D, Golse B, Palacio-Espasa F. 2002. Attentional skills during the first 6 months of age in autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 41(10):1239-45. Mahaffey KR, Clickner RP, Bodurow CC. 2004. Blood organic mercury and dietary mercury intake: national health and nutrition examination survey, 1999 and 2000 . Environ Health Perspect 112(5):562-70. Makani S, Gollapudi S, Yel L, Chiplunkar S, Gupta S. 2002. Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun 3(5):270-8. Makela A, Nuorti JP, Peltola H. 2002. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110(5):957-63. Mann J. 2003. Questions about thimerosal remain. Exp Biol Med 228(9):991-2; discussion 993-4. Mars AE, Mauk JE, Dowrick PW. 1998. Symptoms of pervasive developmental disorders as observed in prediagnostic home videos of infants and toddlers. J Pediatr 132(3 Pt 1):500-4. Micali N, Chakrabarti S, Fombonne E. 2004. The broad autism phenotype: findings from an epidemiological survey. Autism 8(1):21-37. Miller E. 2004. Presentation to the Immunization Safety Review Committee. Thimerosal and Developmental Problems Including Autism. Washington, DC. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, Dean JC. 2000. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37(7):489-97. Mullooly J, Drew L, DeStefano F, Chen R, Okoro K, Swint E, Immanuel V, Ray P, Lewis N, Vadheim C, Lugg M. 1999. Quality of HMO vaccination databases used to monitor childhood vaccine safety. Am J Epidemiol 149(2):186-94. Murch SH, Anthony A, Casson D, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Valentine A, Davies SE, Walker-Smith JA. 2004. Retraction of an Interpretation. Lancet 363:750. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683):386-9. Nelson KB, Bauman ML. 2003. Thimerosal and autism? Pediatrics 111(3):674-9. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, Hansen RL, Phillips TM. 2001. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 49(5):597-606. Nordin J. 2004. Commentary on data presented by the Geiers at the Thimerosal meeting. Email to Immunization Safety Review Committee (firstname.lastname@example.org). March 11. NRC (National Research Council). 1989. Improving Risk Communication. Washington, DC: National Academy Press. NRC. 2000. Toxicological Effects of Methylmercury. Washington, DC: National Academy Press. Osterling J, Dawson G. 1994. Early recognition of children with autism: a study of first birthday home videotapes. J Autism Dev Disord 24(3):247-57. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. 2000. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. [In Process Citation]. Pediatr Infect Dis J 19(12):1127-34.
OCR for page 160
Immunization Safety Review: Vaccines and Autism Pavone P, Bianchini R, Parano E, Incorpora G, Rizzo R, Mazzone L, Trifiletti RR. 2004. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. Pediatr Neurol 30(2):107-10. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. 1998. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study [letter]. Lancet 351(9112):1327-8. Persico AM, D’Agruma L, Maiorano N, Totaro A, Militerni R, Bravaccio C, Wassink TH, Schneider C, Melmed R, Trillo S, Montecchi F, Palermo M, Pascucci T, Puglisi-Allegra S, Reichelt KL, Conciatori M, Marino R, Quattrocchi CC, Baldi A, Zelante L, Gasparini P, Keller F. 2001. Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Mol Psychiatry 6(2):150-9. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. 2002. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 360(9347):1737-41. Plioplys AV. 2000. Intravenous immunoglobulin treatment in autism. J Autism Dev Disord 30(1):73-4. Rapin I. 1997. Autism. New Engl J Med 337(2):97-104. Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, McMahon WM, Petersen PB, Mo A, Ritvo A. 1989a. The UCLA-University of Utah epidemiologic survey of autism: prevalence. Am J Psychiatry 146(2):194-9. Ritvo ER, Jorde LB, Mason-Brothers A, Freeman BJ, Pingree C, Jones MB, McMahon WM, Petersen PB, Jenson WR, Mo A. 1989b. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry 146(8):1032-6. Rogan WJ, Dietrich KN, Ware JH, Dockery DW, Salganik M, Radcliffe J, Jones RL, Ragan NB, Chisolm JJ Jr, Rhoads GG. 2001. The effect of chelation therapy with succimer on neuropsy-chological development in children exposed to lead. N Engl J Med 344(19):1421-6. Rogers SJ, DiLalla DL. 1990. Age of symptom onset in young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 29(6):863-72. Rosenthal S, Chen R, Hadler S. 1996. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 150(5):457-60. Rumsey JM, Ernst M. 2000. Functional neuroimaging of autistic disorders. Ment Retard Dev Disabil Res Rev 6(3):171-9. Rutter M. 1999. The Emanuel Miller Memorial Lecture 1998. Autism: two-way interplay between research and clinical work. J Child Psychol Psychiatry 40(2):169-88. SafeMinds. 2000. VSD subgroup analysis of Spring 2000: Background information on this document. Submitted by S. Bernard on Behalf of SafeMinds. January 18. SafeMinds. 2003. Analysis and critique of the CDC’s handling of the thimerosal exposure assessment based on Vaccine Safety Datalink (VSD) information. Submitted by S. Bernard on Behalf of SafeMinds. January 18:1-46. SafeMinds. 2004a.VSD thimerosal analysis of 2/29/00: Background information on this document. Submitted by S. Bernard on Behalf of SafeMinds. January 18. SafeMinds. 2004b. VSD thimerosal analysis of June 2000: Background information on this document. Submitted by S. Bernard on Behalf of SafeMinds. January 18. SafeMinds. 2004c. VSD Thimerosal Study Protocol: Background information on this document. Submitted by S. Bernard on Behalf of SafeMinds. January 18. Sager P. 2004. Presentation to the Immunization Safety Review Committee. NIAID Studies on Thimerosal. Washington, DC. Salisbury D. 2004. Autism and vaccines. E-mail to Stratton K. January 29, 2004. Attachment: transcript of a High Court hearing in the United Kingdom.
OCR for page 161
Immunization Safety Review: Vaccines and Autism Sandborgh Englund G, Dahlqvist R, Lindelof B, Soderman E, Jonzon B, Vesterberg O, Larsson KS. 1994. DMSA administration to patients with alleged mercury poisoning from dental amalgams: A placebo-controlled study. J Dent Res 73(3):620-28. Schober SE, Sinks TH, Jones RL, Bolger PM, McDowell M, Osterloh J, Garrett ES, Canady RA, Dillon CF, Sun Y, Joseph CB, Mahaffey KR. 2003. Blood mercury levels in US children and women of childbearing age, 1999-2000. JAMA 289(13):1667-74. Sheils O, Smyth P, Martin C, O’Leary JJ. 2002. Development of an ‘allelic discrimination’ type assay to differentiate between the strain origens of measles virus detected in intestinal tissue of children with ileocolonic lymphonodular hyperplasia and concomitant developmental disorder. J Virol 75(2):910-20. Simpsonwood Retreat Center. 2000. Transcript. Scientific Review of Vaccine Safety Datalink Information, June 7-8. Norcross, GA: Simpsonwood Retreat Center. Singh VK. 1996. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 66(1-2):143-5. Singh VK. 2004. Submission to the Immunization Safety Review. Autism, Vaccines, and Immune Reactions. Washington, DC. Singh VK, Fudenberg HH, Emerson D, Coleman M. 1988. Immunodiagnosis and immunotherapy in autistic children. Ann NY Acad Sci 540:602-4. Singh VK, Warren RP, Odell JD, Cole P. 1991. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 61(3):448-55. Singh VK, Warren RP, Odell JD, Warren WL, Cole P. 1993. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 7(1):97-103. Singh VK, Warren R, Averett R, Ghaziuddin M. 1997. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr Neurol 17(1):88-90. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 17:2908-17. Slovic P. 1999. Trust, emotion, sex, politics, and science: surveying the risk-assessment battlefield. Risk Anal 19(4):689-701. Smith CM, Wang X, Hu H, Kelsey KT. 1995. A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Perspect 103(3):248-53. Steffenburg S, Gillberg C, Hellgren L, Andersson L, Gillberg IC, Jakobsson G, Bohman M. 1989. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 30(3):405-16. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. 2003. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 25(2):101-6. Stromland K, Nordin V, Miller M, Akerstrom B, Gillberg C. 1994. Autism in thalidomide embryopathy: a population study. Dev Med Child Neurol 36(4):351-6. Stubbs EG, Crawford ML. 1977. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 7(1):49-55. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, Lougee L, Dow S, Zamkoff J, Dubbert BK. 1998. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 155(2):264-71. Sweeten TL, Bowyer SL, Posey DJ, Halberstadt GM, McDougle CJ. 2003. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 112(5):e420-4. Takahashi H, Suzumura S, Shirakizawa F, Wada N, Tanaka-Taya K, Arai S, Okabe N, Ichikawa H, Sato T. 2003. An epidemiological study on Japanese autism concerning routine childhood immunization history. Jpn J Infect Dis 56(3):114-7. Taylor B, Miller E, Farrington CP. 2000. Response to the MMR question. Lancet 7;356(9237):1273.
OCR for page 162
Immunization Safety Review: Vaccines and Autism Taylor B, Miller E, Farrington CP, Petropoulos MC, Favot-Mayaud I, Li J, Waight PA. 1999. Autism and measles, mumps, and rubella vaccine: No epidemiological evidence for a causal association. Lancet 353(9169):2026-9. Taylor B, Miller E, Lingam R, Andrews N, Simmons ASJ. 2002. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. British Med J 324(7334):393-6. Todd RD, Ciaranello RD. 1985. Demonstration of inter- and intraspecies differences in serotonin binding sites by antibodies from an autistic child. Proc Natl Acad Sci USA 82(2):612-6. Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Walker-Smith JA, Murch SH. 2002. Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 7(4):375-82, 334. Trottier G, Srivastava L, Walker CD. 1999. Etiology of infantile autism: a review of recent advances in genetic and neurobiological research. J Psychiatry Neurosci 24(2):103-15. Tuchman RF, Rapin I. 1997. Regression in pervasive developmental disorders: seizures and epileptiform electroencephalogram correlates. Pediatrics 99(4):560-6. Tuchman RF, Rapin I, Shinnar S. 1991. Autistic and dysphasic children. I: Clinical characteristics. Pediatrics 88(6):1211-8. Uhlmann V, Martin CM, Sheils O, Pilkington L, Silva I, Killalea A, Murch SB, Wakefield AJ, O’Leary JJ. 2002. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. J Clin Pathol: Mol Pathol. 55(2):84-90. Varricchio F. 1998. The vaccine adverse event reporting system. J Toxicol Clin Toxicol 36(7):765-8. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, Chen RT. 2004. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. J Pediatr Infect Dis 23(4):287-94. Verstraeten T. 2001. Presentation to Immunization Safety Review Committee. Vaccine Safety Datalink (VSD) Screening Study and Follow-Up Analysis with Harvard Pilgrim Data. Washington, DC. Verstraeten T. 2004. Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline. Pediatrics 113(4):932. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT, Vaccine Safety Datalink Team. 2003. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 112(5):1039-48. Vojdani A, Campbell AW, Anyanwu E, Kashanian A, Bock K, Vojdani E. 2002. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 129(1-2):168-77. Volkmar F. 2001. Presentation to Immunization Safety Review Committee. Diagnosis of Autism. Washington, DC. Volkmar F, Pauls D. 2003. Autism. Lancet 362:1133-41. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker-Smith JA. 1998. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351(9103):637-41. Wakefield AJ, Anthony A, Murch SH, Thomson M, Montgomery SM, Davies S, O’Leary JJ, Berelowitz M, Walker-Smith JA. 2000. Enterocolitis in children with developmental disorders [see comments]. Am J Gastroenterol 95(9):2285-95. Wakefield AJ, Puleston JM, Montgomery SM, Anthony A, O’Leary JJ, Murch SH. 2002. Review article: the concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 16(4):663-74.
OCR for page 163
Immunization Safety Review: Vaccines and Autism Walsh W, Usman A. 2001. Metallothionein Dysfunction in Children Diagnosed with Autism Spectrum Disorders. Poster: American Psychiatric Accosciation Annual Meeting, May 10, 2001. Pfeiffer Treatment Center, IL. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S, Shim S, Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. 2004. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 9(4):358-70. Warren Grant Magnuson Clinical Center, National Institutes of Health. 2004. Preparing for Transfusion Therapy. Online: http://www.healthfinder.gov/orgs/HR0022.htm. Warren RP, Margaretten NC, Pace NC, Foster A. 1986. Immune abnormalities in patients with autism. J Autism Dev Disord 16(2):189-97. Warren RP, Foster A, Margaretten NC. 1987. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatry 26(3):333-5. Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, White E. 1991. Increased frequency of the null allele at the complement C4b locus in autism. Clin Exp Immunol 83(3):438-40. Warren RP, Singh VK, Cole P, Odell JD, Pingree CB, Warren WL, DeWitt CW, McCullough M. 1992. Possible association of the extended MHC haplotype B44-SC30-DR4 with autism. Immunogenetics 36(4):203-7. Warren RP, Odell JD, Warren WL, Burger RA, Maciulis A, Daniels WW, Torres AR. 1996. Strong association of the third hypervariable region of HLA-DR beta 1 with autism. J Neuroimmunol 67(2):97-102. Wassink TH, Piven J, Vieland VJ, Huang J, Swiderski RE, Pietila J, Braun T, Beck G, Folstein SE, Haines JL, Sheffield VC. 2001. Evidence supporting WNT2 as an autism susceptibility gene. Am J Med Genet 105(5):406-13. Watson JC, Redd SC, Rhodes PH, Hadler SC. 1998. The interruption of transmission of indigenous measles in the United States during 1993. Pediatr Infect Dis J 17(5):363-6; discussion 366-7. Weed DL, Hursting SD. 1998. Biologic plausibility in causal inference: current method and practice. Am J Epidemiol 147(5):415-25. Wentz P.W. 2000. Chelation therapy: conventional treatments. Advance/Laboratory. Available at http://www.advanceforAL.com. Werner E, Dawson G, Munson J, Osterling J. In Press. Variation in early developmental course in autism and its relation with behavioral outcome at 3-4 years of age. J Autism Dev Disorder. Wilson GS. 1967. The Hazards of Immunization. New York: The Athlone Press. Pp. 75-84. Wilson K. 2004. Presentation to the Immunization Safety Review Committee. Washington, DC. Wilson K, Mills E, Ross C, McGowan J, Jadad A. 2003. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 157(7):628-34. Wing L, Potter D. 2002. The epidemiology of autistic spectrum disorders: is the prevalence rising? Mental Ret Dev Disabil Res Rev 8:151-61. Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. 2003. Prevalence of autism in a US metropolitan area. JAMA 289(1):49-55. Zimmerman AW. 2000. Commentary: immunological treatments for autism: in search of reasons for promising approaches. J Autism Dev Disord 30(5):481-4. Zoghbi HY. 2003. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302(5646):826-30.
OCR for page 164
Immunization Safety Review: Vaccines and Autism This page intentionally left blank.
Representative terms from entire chapter: